Forest Labs Reps Marketed Daliresp Off-Label, FDA Says

Law360, New York (August 9, 2012, 4:39 PM EDT) -- The U.S. Food and Drug Administration has accused Forest Laboratories Inc. of allowing two sales representatives to push its chronic obstructive pulmonary disease drug Daliresp for off-label use, despite a promotional integrity agreement reached with the agency as part of a $313 million off-label marketing settlement.

In a warning letter dated Aug. 1 but made publicly available Tuesday, the FDA’s Office of Prescription Drug Promotion says an unnamed doctor reported the Forest sales reps under an FDA program that encourages the reporting of misbranding by drug...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.